Literature DB >> 8640808

Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls.

M G Muto1, D W Cramer, J Tangir, R Berkowitz, S Mok.   

Abstract

Among women of Ashkenazi Jewish origin, a frameshift mutation of the BRCA1 gene, designated 185delAG, occurs with a carrier frequency of approximately 1% and is estimated to account for about 39% of ovarian cancer cases occurring prior to age 50 years. To determine the actual frequency of this mutation among Jewish women with ovarian cancer, we tested DNA collected as part of an ongoing population-based case-control study of genetic and environmental factors for epithelial ovarian cancer in eastern Massachusetts. Using single-stranded conformational polymorphism analysis followed by direct sequencing, we found that 6 (19.4%) of 31 Jewish patients were carriers for a 185delAG mutation compared to 0 of 23 Jewish controls (P=0.03) Using empiric logic [correction of logits], the estimated relative risk for ovarian cancer associated with a 185delAG mutation is 12.0. The average age of the 6 patients with mutations was 48.3 years, significantly younger than the average of 57.4 years observed for the 25 patients without the mutation (P-0.05). For ovarian cancer diagnosed prior to age 50 years, three (37.5%) of eight patients carried the mutation. None of the six patients with the mutation had a history consistent with hereditary breast ovarian cancer syndrome, although two had a personal history of prior cancer. Our results provide empiric conformation of the estimated prevalence of 185delAG mutations among Jewish women with ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640808

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  Recent advances in breast cancer genetics.

Authors:  Boris Pasche
Journal:  Cancer Treat Res       Date:  2008

2.  The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Authors:  D Abeliovich; L Kaduri; I Lerer; N Weinberg; G Amir; M Sagi; J Zlotogora; N Heching; T Peretz
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

3.  BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.

Authors:  R Moslehi; W Chu; B Karlan; D Fishman; H Risch; A Fields; D Smotkin; Y Ben-David; J Rosenblatt; D Russo; P Schwartz; N Tung; E Warner; B Rosen; J Friedman; J S Brunet; S A Narod
Journal:  Am J Hum Genet       Date:  2000-03-16       Impact factor: 11.025

4.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

Authors:  H A Risch; J R McLaughlin; D E Cole; B Rosen; L Bradley; E Kwan; E Jack; D J Vesprini; G Kuperstein; J L Abrahamson; I Fan; B Wong; S A Narod
Journal:  Am J Hum Genet       Date:  2001-02-15       Impact factor: 11.025

5.  Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.

Authors:  S V Hodgson; E Heap; J Cameron; D Ellis; C G Mathew; R A Eeles; E Solomon; C M Lewis
Journal:  J Med Genet       Date:  1999-05       Impact factor: 6.318

6.  Nonsense mutation at codon 63 of the BRCA1 gene in Japanese breast cancer patients.

Authors:  G Kijima; Y Murakami; N Ohuchi; S Satomi; T Sekiya
Journal:  Jpn J Cancer Res       Date:  1998-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.